Phase 3 Schizophrenia Trial, Recruiting NCT05796401 Sponsor: Centre Hospitalier St Anne Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT05796401
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 15 to 30 years, of any sex
  • People identified using a specific clinical assessment tool (called CAARMS) as either at high risk of developing psychosis, or within the first year after a first episode of psychosis diagnosis and care
  • People who are able to provide written, informed consent to participate
  • People who have regular health insurance coverage

Who may not be able to join:

  • People with serious medical conditions that are not yet stable or controlled
  • People who do not have a sufficient ability to read or communicate in French
  • People who are currently taking part in another intervention trial or a full cognitive rehabilitation programme
  • People who are currently hospitalised under enforced (involuntary) conditions
  • People with an intellectual disability (IQ below 70) or sensory or motor difficulties that would make cognitive training activities not possible
  • People who have previously had a treated episode of psychosis, or have a long-standing diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder prior to the 12-month window specified in the inclusion criteria
  • People currently experiencing severe depression (confirmed with a specific rating scale score above 34, if there is doubt)
  • People who have been taking antipsychotic medications at treatment-level doses for more than 12 months
  • People currently taking benzodiazepine medications at a daily dose equivalent to more than 30mg of diazepam
  • People who currently use substances (other than nicotine and alcohol) on a daily basis at an amount greater than the equivalent of 5 cannabis cigarettes per day, and/or people meeting criteria for a severe substance use disorder (other than nicotine) within the past 6 months or for more than 5 years
  • People who are pregnant, recently given birth, or currently breastfeeding
  • People whose freedom is restricted by a legal or administrative order, or who are under involuntary psychiatric care under specific French public health law provisions
  • Adults who are under a legal protection measure or who are not able to give consent on their own behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +33 1 45 65 74 97

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Centre Hospitalier St Anne
Registry
ClinicalTrials.gov
Start date
15 December 2023
Est. completion
15 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Global functioning

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov